CB3: The Third Cannabinoid Receptor


The discovery of the endocannabinoid system very well may be the most significant breakthrough regarding the human anatomy in the past century. Since the first cannabinoids were isolated and the discovery of the CB1 and CB2 receptors has become public knowledge the movement to bring this plant to the people has been unstoppable. The CB1 and CB2 receptors are receptors located throughout the body of every living mammal in what is known as the endocannabinoid system. Cannabinoid receptors such as CB1 and CB2 receptors are biochemical receptors that receive chemical signals from a source external to their molecule. These signals are dormant without the introduction of cannabinoids from cannabis to the body.

This system and these receptors work together with phytocannabinoids from the cannabis plant to bring patients relief from a plethora of different elements. The ECS is a crucial part of the central nervous system that helps to regulate everything from appetite and pain sensation to cognitive processes and much more. It is because of this that cannabis is effective in providing relief from so many different diseases and conditions.

Just recently, as more research has been performed on the components of the Endocannabinoid System, researchers have discovered there is another molecule that could soon be classified as the third cannabinoid receptor or CB3. This molecule known as GPR55 was found in the late 1990s throughout the brain in the thalamus, cerebellum, and hippocampus. More recent research has also located it in the adrenal glands, gastrointestinal tract, and the spleen. 

GPR55 is also present in cancer cells which could open the door to us learning more about cancer itself than we have ever before. If this molecule is classified as CB3, it will solidify the fact that we have only scratched the surface when it comes to our knowledge surrounding this vital system in our bodies. It could also mean a whole new understanding of how to better fight deadly conditions such as various cancer types.

July 23, 2018

by Ashley Priest

Profile photo of Ashley Priest
Ashley is a freelance cannabis writer and the co-owner of CannaLance. Her passion for sharing education and truth surrounding cannabis stems from a personal loss. Ashley has always had an elevated relationship with cannabis but it wasn't until 2015 that she turned that passion and relationship into a career as a cannabis writer.


The Blazing Facebook Battle 
The Rise Of Cannabis Beverages
Cannabis Culture While Traveling
Bring Your Cannabis Camping
Ontario Feeling Whiplash After Recent Announcement
Canadian Cannabis Farmers To Qualify For Funding And Support
CBD In The Cosmetic Industry
High Times IPO Opens The Door To Crypto Investors
The Role Of Enzymes: What The FAAH?!
Can You Become Addicted To CBD?
Can Cannabis Help Your Anxiety?
Canada’s Medical Cannabis Program Is Being Challenged
Fastest Ways To Get High
Some People Can’t Handle Weed
How Legalized Recreational Cannabis Will Help Medical Consumers
Patiently Waiting For Infused & Extracted Cannabis Products